PA
RAPP

Profund Advisors’s Rapport Therapeutics RAPP Stock Holding History

Profund Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,880
Closed -$269K – 1313
2025
Q4 		$269K Buy
+8,880
New +$246K 0.01% 954

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Profund Advisors's RAPP Position: Q1 2026 in Review

Profund Advisors sold out of Rapport Therapeutics (RAPP) in Q1 2026, closing a stake of 8,880 shares — an estimated $269K sold.

Profund Advisors first reported a position in RAPP in Q4 2025 and held it in 1 quarter. The position peaked at $269K in Q4 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Profund Advisors reported no remaining Rapport Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Profund Advisors sold 8,880 Rapport Therapeutics shares in Q1 2026, an estimated $269K.
  • Profund Advisors first reported a position in Rapport Therapeutics in Q4 2025 and held it in 1 quarter.
  • Profund Advisors's Rapport Therapeutics position peaked at $269K in Q4 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.